Literature DB >> 17903725

Angiotensin II type 2 receptor provides an endogenous brake during inflammation-induced microvascular fluid leak.

Alexander Q Ereso1, René M Ramirez, Javid Sadjadi, Michael W Cripps, Elizabeth L Cureton, Brian Curran, Gregory P Victorino.   

Abstract

BACKGROUND: The dual actions of angiotensin II (AngII) on microvascular fluid leak remain enigmatic. Our hypothesis was that the AngII type 2 (AT2) receptor decreases microvascular fluid leak during inflammation. The purposes of this study were to determine the activity of the AT2 receptor during stimulation by endogenous AngII, during stimulation by exogenous AngII, and during inflammation. STUDY
DESIGN: Hydraulic permeability (L(p)) of rat mesenteric venules was measured using a microcannulation technique. L(p) was measured during perfusion with the AT1 receptor antagonist, ZD7155, and also with exogenous AngII during AngII type 1 receptor (AT1) blockade. Inflammation was induced with platelet activating factor (PAF), and L(p) was measured during perfusion of AngII with AT1 blockade and also with an AT2 receptor agonist, CGP42112.
RESULTS: AT2 receptor activation by endogenous AngII slightly decreased L(p) over that of the control (p=0.02). Exogenous AngII increased L(p) fivefold (L(p)=4.83+/-1.32; p < 0.001). Addition of AT1 receptor blockade decreased L(p) by 74% (to 1.24+/-0.03; p < 0.01). PAF activation increased L(p) fourfold (L(p)=4.49+/-0.74; p < 0.0001). After PAF activation, exogenous AngII then decreased L(p) by 39% (to 2.74+/-0.12; p < 0.01). Exogenous AngII during AT1 receptor blockade after PAF activation decreased L(p) by 61% (from 4.49+/-0.74 to 1.77+/-0.22; p < 0.0001), and selective AT2 receptor stimulation after PAF activation decreased L(p) by 69% (from 4.49+/-0.74 to 1.40+/-0.04; p < 0.001).
CONCLUSIONS: This study further supports a dual role for AngII. AngII increases microvascular fluid leak during basal conditions but appears to decrease it during inflammation. Alterations in AT2 receptor activity may be responsible for these different effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17903725     DOI: 10.1016/j.jamcollsurg.2007.07.026

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  3 in total

1.  Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.

Authors:  Daniel E Leisman; Clifford S Deutschman; Matthieu Legrand
Journal:  Intensive Care Med       Date:  2020-04-28       Impact factor: 17.440

2.  Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019-Induced Vasodilatory Shock: A Retrospective Matched Cohort Study.

Authors:  Daniel E Leisman; Fiore Mastroianni; Grace Fisler; Sareen Shah; Zubair Hasan; Mangala Narasimhan; Matthew D Taylor; Clifford S Deutschman
Journal:  Crit Care Explor       Date:  2020-09-29

3.  Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).

Authors:  Matthieu Legrand; Emmanuel Futier; Marc Leone; Benjamin Deniau; Alexandre Mebazaa; Benoît Plaud; Pierre Coriat; Patrick Rossignol; Eric Vicaut; Etienne Gayat
Journal:  Trials       Date:  2019-03-05       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.